Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06), Zacks reports.
Corvus Pharmaceuticals Price Performance
Shares of CRVS stock traded up $0.01 during midday trading on Friday, hitting $3.38. The company had a trading volume of 647,385 shares, compared to its average volume of 580,680. The stock has a market cap of $217.19 million, a price-to-earnings ratio of -3.63 and a beta of 0.91. The company's 50 day simple moving average is $4.61 and its 200 day simple moving average is $6.06. Corvus Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $10.00.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on CRVS. Oppenheimer reissued an "outperform" rating and issued a $15.00 price target (up from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.67.
Read Our Latest Stock Analysis on Corvus Pharmaceuticals
About Corvus Pharmaceuticals
(
Get Free Report)
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Further Reading
Before you consider Corvus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.
While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
